ÂÜÀòÂÒÂ×

James Mallinson has over 25 years’ experience in venture capital. He has made investments in, and been closely involved with the development of, many technology companies including: NaturalMotion, acquired by Zynga Inc for over $527m in February 2014; Oxford Immunotec, which raised $64m on the NASDAQ stock exchange in November 2013; Yasa Motors, a privately held company developing class leading very high power to weight ratio electric motors; Adaptimmune, floated on NASDAQ in May 2015 raising $171m; Crysalin, which is developing new techniques for protein structure determination, and many others. He is Director of Spin-out Equity Management at Oxford University Innovation where he has been since 2003. As Director of Spinout Equity Management he manages the University of Oxford’s portfolio of shareholdings in its 104 technology spin-out companies. Prior to his time at the University of Oxford (including at Isis Innovation, the previous name for Oxford University Innovation and the technology transfer company of the University of Oxford) he was an investment executive in the venture capital and private equity group at Abbey National Treasury Services where he managed technology venture investments as a member of a team of 11 responsible for commitments of £1.9bn; He has also been a member of the Strategic Advisory Board of funds managed by Advent Venture Partners and Avlar BioVentures. He is an Engineering Science graduate from the University of Oxford, and gained his MBA from Cranfield University in 1990.